Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258
Hemostemix has completed its second and final tranche of private placement, raising $833,258 through the issuance of 16,665,160 Units at $0.05 per Unit. The combined offerings totaled $2,675,981.77 with 53,519,635 Units issued. Each Unit includes one common share and one warrant exercisable at $0.12 per share for 24 months. The proceeds will fund the company's stem cell therapeutics platform, initiate ACP sales, and cover operational expenses. The company paid approximately $24,820.64 in finder fees and issued 496,413 finder's options.
Hemostemix ha completato la sua seconda e ultima tranche di collocamento privato, raccogliendo $833,258 attraverso l'emissione di 16,665,160 Unità a $0.05 per Unità. Le offerte combinate hanno totalizzato $2,675,981.77 con 53,519,635 Unità emesse. Ogni Unità include una azione ordinaria e un warrant esercitabile a $0.12 per azione per un periodo di 24 mesi. I proventi finanzieranno la piattaforma di terapie con cellule staminali della società, avvieranno le vendite di ACP e copriranno le spese operative. La società ha pagato circa $24,820.64 in commissioni per i broker e ha emesso 496,413 opzioni per i broker.
Hemostemix ha completado su segunda y última tranche de colocación privada, recaudando $833,258 a través de la emisión de 16,665,160 Unidades a $0.05 por Unidad. Las ofertas combinadas sumaron $2,675,981.77 con 53,519,635 Unidades emitidas. Cada Unidad incluye una acción ordinaria y una warranty ejercitable a $0.12 por acción durante 24 meses. Los ingresos financiarán la plataforma de terapias con células madre de la empresa, iniciarán las ventas de ACP y cubrirán los gastos operativos. La empresa pagó aproximadamente $24,820.64 en comisiones a intermediarios y emitió 496,413 opciones para intermediarios.
Hemostemix는 두 번째이자 마지막 개인 배급의 단계를 완료했으며, 16,665,160 유닛을 $0.05의 가격으로 발행하여 총 $833,258을 모금했습니다. 전체 제공 금액은 $2,675,981.77로, 53,519,635 유닛이 발행되었습니다. 각 유닛은 보통 주식 1주와 24개월 동안 $0.12에 행사 가능한 보증서 1장을 포함합니다. 수익금은 회사의 줄기 세포 치료 플랫폼에 자금을 지원하고, ACP 판매를 시작하며, 운영 비용을 충당하는 데 사용됩니다. 회사는 중개 수수료로 약 $24,820.64을 지불했고, 496,413개의 중개업체 옵션을 발행했습니다.
Hemostemix a complété sa deuxième et dernière tranche de placement privé, levant $833,258 par l'émission de 16,665,160 unités au prix de $0.05 par unité. Les offres combinées ont totalisé $2,675,981.77 avec 53,519,635 unités émises. Chaque unité comprend une action ordinaire et un bon de souscription exerçable à $0.12 par action pendant 24 mois. Les fonds serviront à financer la plateforme de thérapies par cellules souches de l'entreprise, à initier les ventes d'ACP et à couvrir les frais d'exploitation. L'entreprise a payé environ $24,820.64 en frais de courtage et a émis 496,413 options pour courtiers.
Hemostemix hat seine zweite und letzte Tranche der Privatplatzierung abgeschlossen und $833,258 durch die Ausgabe von 16,665,160 Einheiten zu einem Preis von $0.05 pro Einheit gesammelt. Die kombinierten Angebote betrugen $2,675,981.77 mit insgesamt 53,519,635 ausgegebenen Einheiten. Jede Einheit umfasst eine Stammaktie und einen Warrants, der für 24 Monate zu einem Preis von $0.12 pro Aktie ausgeübt werden kann. Die Einnahmen werden zur Finanzierung der Stammzelltherapie-Plattform des Unternehmens, zur Einleitung des ACP-Verkaufs und zur Deckung der Betriebskosten verwendet. Das Unternehmen zahlte etwa $24,820.64 in Vermittlungsgebühren und gab 496,413 Vermittlungsoptionen aus.
- Successful completion of private placement raising $2.67M in total proceeds
- Additional capital to advance stem cell therapeutics platform
- Funding secured for initiating ACP sales and production
- Significant dilution through issuance of 53.5M new units
- Warrants may cause further dilution if exercised
- Related party participation in the offering
Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its second and final tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of
If, during any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date of the Offering, the weighted average closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange ("Exchange") is greater than or equal to
In connection with the Offering, the Company paid eligible finders aggregate cash finder fees of approximately
The combined Offerings resulted in gross proceeds of
The Offering is subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
For further details regarding the Company's Offering, please refer to the Company's News Releases dated October 11, 2024 and October 31, 2024. The Offering included subscribers under the investment dealer exemption. In accordance with the requirements of the investment dealer exemption, the Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.
Certain directors of the Company participated in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSXV. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds
About Hemostemix
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. For more information, please visit Hemostemix.com.
For further information, please contact:
Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com
PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the financing of the Company and its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under physician order. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231858
FAQ
How much did Hemostemix (HMTXF) raise in its second tranche of private placement?
What is the total amount raised by Hemostemix (HMTXF) in the combined offerings?
What is the exercise price and term of the warrants issued in Hemostemix's (HMTXF) private placement?
How will Hemostemix (HMTXF) use the proceeds from the private placement?
